

OKLAHOMA BOARD OF NURSING
2915 N. Classen Boulevard, Suite 524
Oklahoma City, Oklahoma 73106

**CRNA Formulary Advisory Committee
Minutes-April 23, 2018**

The CRNA Formulary Advisory Council (“Council”) to the Oklahoma Board of Nursing (“Board”) met on April 23, 2018. Notice of the meeting was initially filed with the Secretary of State’s Office on December 12, 2017. Notice of the meeting was posted on the Oklahoma Board of Nursing web site not less than 24 hours prior to the meeting. A notice/agenda was also posted on the Cameron Building front entrance at 2915 North Classen Boulevard, Oklahoma City, Oklahoma, as well as the Board office at 2915 North Classen, Suite 524, at 4 PM on April 9, 2018 and not less than 24 hours prior to the meeting.

Place of Meeting: Basement Conference Room, Cameron Building

Time of Meeting: 3:30 PM

Members Present: Mark St Cyr, D.Ph.
Oklahoma Pharmacists Association

Lad Yates, MD
Oklahoma Society of Anesthesiologists

Thomas Tinker, MD
Oklahoma Society of Anesthesiologists

Victor Long, APRN-CRNA
Oklahoma Association of Nurse Anesthetists

Members Absent: Bruce Kennedy, APRN-CRNA
Oklahoma Association of Nurse Anesthetists

Board Representative: Susan Jones, Ph.D, APRN-CNS
Jan Palovik, MS, APRN-CRNA (absent)

Staff Representatives: Jackye Ward, MS, RN
Gina Stafford, RN

Guest: None

1.0 Call to order: The meeting was called to order at 3:30 PM by Dr. Tinker, Chairperson.

1.1 Declaration of a quorum: A quorum was declared present.

2.0 Minutes of the previous meeting – May 15, 2017: The minutes were reviewed. A motion was made (M. St Cyr) and seconded to approve the minutes of May 15, 2017.

Voting:

Yes: (4) V. Long, M. St Cyr, T. Tinker, L. Yates
No: (0)
Absent: (1) B. Kennedy

Motion Carried.

3.0 Board of Nursing update (verbal reports requiring no action by Committee):

- 3.1 Changes to the *Oklahoma Nursing Practice Act (HB1886)*:** J. Ward summarized changes to the *Oklahoma Nursing Practice Act* specific to Advanced Practice Registered Nurses (APRN) that went into effect November 1, 2017.
- 3.2 Proposed Amendments to the *Oklahoma Nursing Practice Act (HB 2518)*:** J. Ward summarized proposed amendments to the *Nursing Practice Act*.
- 3.3 Revisions submitted for approval for the *Rules of the Oklahoma Board of Nursing*:** J. Ward summarized proposed changes to the *Rules* specific to APRNs allowing an APRN to endorse licensure into Oklahoma with a retired certification, if licensure has remained active and uninterrupted.
- 3.4 New Enhanced Nurse Licensure Compact:** J. Ward reported 1,132 multistate license applications, 285 endorsement applications and 450 new multistate license applications RN/LPN have been processed and licenses have been issued with an average processing time of 1.5 days.
- 3.5 Board decision on policy revisions:** G. Stafford reviewed changes to the *Exclusionary Formulary for Advanced Practice Registered Nurses with Prescriptive Authority*.
- 3.6 The *Oklahoma Commission on Opioid Abuse Final Report*:** G. Stafford reviewed the recommendations of the report with the Council.
- 3.7 OBN Website-Reduce Opioid Overdose:** G. Stafford reported changes to the website to include resources to help educate nurses and prevent opioid overdose.
- 3.8 RN First Assistant: Second Declaratory Ruling:** G. Stafford informed the Council of updates to the AORN position statements.
- 3.9 AORN Position Statement of APRN in the Perioperative Environment:** G. Stafford provided the AORN educational requirements for an APRN to work as an RN First Assistant.
- 3.10 CRNA Formulary Advisory Council members:** G. Stafford reviewed expiration of appointments with the Council.
- 3.11 Other:** no other reports

4.0 Review and committee recommendations on revisions to *CRNA Inclusionary Formulary*: Council members reviewed the DRAFT *CRNA Inclusionary Formulary*, #P-50 with proposed revisions. A list of new and updated monographs was provided to

committee members. The proposed revisions add new cross-references; identify drugs that remain on the market but for which no monograph is provided in the current edition of the *AHFS Drug Information Manual*. After discussion, it was moved (V. Long) and seconded to recommend the following revisions to the *CRNA Inclusionary Formulary*, #P-50 to the Board for approval:

- Add asterisk on the following drugs no longer included in the print version on the *AHFS Drug Information*:
 - Physotigmine Salicylate 12:04
 - Pyridostigmine Bromide 12:04
 - Isoproterenol 12:12.08.04
 - Atracurium Besylate 12:20.20
 - Pancuronium Bromide 12:20.20
 - Protamine Sulfate 20:28.08
 - Sodium Chloride 40:12
 - Benzocaine 52:16
 - Proparacaine 52:16
 - Dolasetron 56:22.20
 - Glimepiride 68:20.20

- Add two categories of Muscle Relaxants and drugs:
 - Centrally Acting Skeletal Muscle Relaxants 12:20.04
 - GABA-derivative Skeletal Muscle Relaxants 12:20.12

- Add one new category including a new drug
 - Renin-Angiotensin-Aldosterone System (RAAS) with the drug Angiotensin II 68:44

- Remove one category with one drug
 - Other Miscellaneous Therapeutic Agents with the drug Adenosine Phosphate 92:92

- Update the reference for *AHFS Drug Information* to the current edition (2018)

- Alphabetize two categories, 12:12.08 and 12:20.20

- Change the website address for Codeine precautions

- Add language regarding Ketamine *not in AHFS*

Voting:

Yes: (4) V. Long, M. St Cyr, T. Tinker, L. Yates
No: (0)
Absent: (1) B. Kennedy

Motion Carried.

- 5.0 Election of Chairperson and Vice Chairperson for 2019:** It was moved (L. Yates) and seconded to appoint Dr. Tinker as Chairperson and to appoint Bruce Kennedy as Vice Chairperson for the next CRNA Formulary Advisory Council Meeting.

Voting:

Yes: (4) V. Long, M. St Cyr, T. Tinker, L. Yates
No: (0)
Absent: (1) B. Kennedy

Motion Carried.

- 6.0 Date for next meeting:** The members discussed possible dates and times for the next meeting.

6.1 Selected date and time for the next meeting will be Monday, April 22, 2019 at 3:30 PM.

Voting:

Yes: (4) V. Long, M. St Cyr, T. Tinker, L. Yates
No: (0)
Absent: (1) B. Kennedy

Motion Carried.

- 7.0 Adjournment:** There being no further business, the meeting was adjourned at 4:26 PM.